Compare Stocks

Enter up to five stock symbols separated by a comma or space (ex. BAC,WFC,JPM,LON:BARC).

Date Range:

	NTN Buzztime	Benitec Biopharma	Mateon Therapeutics	Q BioMed	Artelo Biosciences
Symbol	NYSEAMERICAN:NTN	NASDAQ:BNTC	OTCMKTS:MATN	OTCMKTS:QBIO	NASDAQ:ARTL
Price Information
Current Price	$32.30	$4.35	$0.32	$1.03	$1.23
52 Week Range	N/A	Hold	Buy	N/A	Buy
MarketRank™
Overall Score	0.4	0.6	1.5	0.5	1.6
Analysis Score	0.0	0.0	3.5	0.0	3.5
Community Score	2.0	2.3	2.6	2.6	2.7
Dividend Score	0.0	0.0	0.0	0.0	0.0
Ownership Score	0.0	0.0	0.8	0.0	1.7
Earnings & Valuation Score	0.0	0.6	0.6	0.0	0.0
Analyst Ratings
Consensus Recommendation	N/A	Hold	Buy	N/A	Buy
Consensus Price Target	N/A	N/A	$3.00	N/A	$7.00
% Upside from Price Target	N/A	N/A	852.38% upside	N/A	469.11% upside
Trade Information
Market Cap	$96.16 million	$20.96 million	$28.43 million	$26.78 million	$28.45 million
Beta	0.72	1.84	1.52	2.1	2.52
Average Volume	1,629,816	2,053,399	338,444	105,821	6,794,023
Sales & Book Value
Annual Revenue	$19.81 million	$100,000.00	N/A	N/A	N/A
Price / Sales	4.85	209.58	N/A	N/A	N/A
Cashflow	$7.37 per share	$4.39 per share	N/A	N/A	N/A
Price / Cash	4.38	0.99	N/A	N/A	N/A
Book Value	$1.76 per share	$19.75 per share	$0.20 per share	($0.26) per share	$0.78 per share
Price / Book	18.35	0.22	N/A	N/A	N/A
Profitability
Net Income	$-2,050,000.00	$-8,270,000.00	$-6,640,000.00	$-10,280,000.00	$-4,660,000.00
EPS	N/A	($8.10)	N/A	N/A	N/A
Trailing P/E Ratio	N/A	N/A	0.00	N/A	N/A
Forward P/E Ratio	∞	∞	N/A	∞	∞
P/E Growth	N/A	N/A	N/A	N/A	N/A
Net Margins	-61.42%	N/A	N/A	N/A	N/A
Return on Equity (ROE)	-162.54%	N/A	-64.66%	N/A	-96.32%
Return on Assets (ROA)	-49.94%	N/A	-42.92%	-678.41%	-88.73%
Dividend
Annual Payout	N/A	N/A	N/A	N/A	N/A
Dividend Yield	N/A	N/A	N/A	N/A	N/A
Three-Year Dividend Growth	N/A	N/A	N/A	N/A	N/A
Payout Ratio	N/A	N/A	N/A	N/A	N/A
Years of Consecutive Dividend Growth	N/A	N/A	N/A	N/A	N/A
Debt
Debt-to-Equity Ratio	3.30%	N/A	N/A	N/A	N/A
Current Ratio	0.95%	N/A	0.17%	0.88%	15.43%
Quick Ratio	0.95%	N/A	0.17%	0.88%	15.43%
Ownership Information
Institutional Ownership Percentage	6.31%	5.72%	0.04%	0.04%	N/A
Insider Ownership Percentage	24.20%	1.00%	39.22%	N/A	3.36%
Miscellaneous
Employees	19	14	13	4	3
Shares Outstanding	2.98 million	4.82 million	90.24 million	26.12 million	23.13 million
Next Earnings Date	5/18/2021 (Estimated)	N/A	N/A	7/21/2021 (Estimated)	7/12/2021 (Estimated)
Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable	Not Optionable

Source	Headline
	Artelo Biosciences to Participate at the Benzinga Global Small Cap Conference on May 13, 2021 finance.yahoo.com - May 6 at 8:30 AM
	Kintara Therapeutics Appoints Tamara A. Seymour to Board of Directors finance.yahoo.com - May 4 at 8:33 AM
	Artelo Biosciences, Inc. (NASDAQ:ARTL) Jumps 1.18%: A Look At The most Likely Path Going Forward stocksregister.com - April 24 at 5:42 PM
	Financial Comparison: Enochian Biosciences (NASDAQ:ENOB) vs. Artelo Biosciences (NASDAQ:ARTL) americanbankingnews.com - April 21 at 10:14 PM
	Artelo Biosciences Inc. [ARTL] gain 72.60% so far this year. What now? dbtnews.com - April 20 at 3:46 PM
	We're Hopeful That Artelo Biosciences (NASDAQ:ARTL) Will Use Its Cash Wisely finance.yahoo.com - April 20 at 10:46 AM
	Analysts think Artelo Biosciences, Inc. (NASDAQ:ARTL) could rise 503.45% from current levels stocksregister.com - April 19 at 12:39 PM
	Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update \| Morningstar morningstar.com - April 15 at 6:06 PM
	Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss \| Morningstar morningstar.com - April 14 at 5:43 AM
	Artelo Biosciences Reports Second Quarter Fiscal 2021 Financial Results and Provides Business Update finance.yahoo.com - April 13 at 9:29 AM
	Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of ... apnews.com - April 12 at 1:16 PM
	Artelo Biosciences Doses First Patient in CAReS Study with ART27.13 for the Treatment of Cancer-Related Anorexia and Weight Loss finance.yahoo.com - April 12 at 1:16 PM
	Will Artelo Biosciences (NASDAQ:ARTL) Spend Its Cash Wisely? nasdaq.com - April 8 at 8:22 AM
	Artelo Biosciences, Inc. (ARTL) CEO Gregory Gorgas Presents at Q1 Virtual Investor Summit Conference (Transcript) seekingalpha.com - March 25 at 10:34 AM
	Artelo Biosciences Inc. (NASDAQ: ARTL) Featured in Virtual Coverage of Investor Summit Group's Q1 Virtual Summit marketwatch.com - March 23 at 8:59 AM
	Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 ... apnews.com - March 20 at 8:20 AM
	Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development finance.yahoo.com - March 19 at 2:28 PM
	Artelo Biosciences Accepted into the Alderley Park Oncology Development Program for FABP5 Inhibitor Biomarker Development finance.yahoo.com - March 19 at 2:28 PM
	Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd markets.businessinsider.com - March 11 at 9:25 AM
	Artelo Biosciences, Inc. to Present at the Q1 Virtual Investor Summit on March 23rd finance.yahoo.com - March 11 at 9:25 AM
	Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to ... apnews.com - March 10 at 8:57 AM
	ARTL Stock Price Increases Over 30% Pre-Market: Why It Happened pulse2.com - March 10 at 8:57 AM
	Artelo Biosciences Appoints Finance and Healthcare Industry Executive Tamara A. Seymour to Board of Directors finance.yahoo.com - March 9 at 8:57 AM
	Artelo Biosciences to Present at the H.C. Wainwright Global Life Sciences Conference on March 9th finance.yahoo.com - March 2 at 8:49 AM
	What To Know About Artelo Bio And Trinity College's Partnership For Cannabinoid And Cancer Research benzinga.com - February 19 at 5:39 PM

Date	Company	Brokerage	Action
10/5/2020	Benitec Biopharma	LADENBURG THALM/SH SH	Downgrade
12/7/2020	Mateon Therapeutics	Litchfield Hills Research	Initiated Coverage
4/22/2019	Mateon Therapeutics	HC Wainwright	Reiterated Rating
5/10/2019	Q BioMed	Brookline Capital Management	Reiterated Rating
11/29/2018	Q BioMed	Roth Capital	Downgrade
1/7/2021	Artelo Biosciences	Maxim Group	Upgrade

(Data available from 5/11/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Comparison Ideas:

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here

Your Ultimate Investing Toolkit

Just $1.00 for your first month.

Compare Stocks

30 Days of MarketBeat All Access for $1.00

Resources

Premium Research Tools

Market Data and Calendars

Investing Education and Resources